Nexvet Biopharma plc
NVET evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Lead Asset:
- frunevetmab (Phase 2)
What it means
What to watch
Prepared research question
What matters most for NVET—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
frunevetmab (Phase 2)
Next Catalyst
—
Tracking 2 pipeline candidates for Nexvet Biopharma plc.
Run Nexvet Biopharma plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nexvet Biopharma plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is Nexvet Biopharma plc's lead drug candidate?
Nexvet Biopharma plc's most advanced tracked candidate is frunevetmab (Phase 2) for chronic pain associated with osteoarthritis in cats.
Who is the CEO of Nexvet Biopharma plc?
Mark Heffernan, Ph.D. is the chief executive officer of Nexvet Biopharma plc (NVET).
What therapeutic areas does Nexvet Biopharma plc focus on?
Nexvet Biopharma plc develops therapies across Oncology, Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.